Literature DB >> 2428860

Graves' disease and Hashimoto's thyroiditis: effects of high doses of antithyroid drugs on thyroid autoantibody levels.

J H Romaldini, M C Werner, H F Rodrigues, V L Teixeira, R S Werner, C S Farah, N Bromberg.   

Abstract

We studied the effects of high doses of methimazole (MMI) or propylthiouracil (PTU) on thyroid-stimulating antibody (TSAb), antithyroid microsomal (MCHA) and antithyroglobulin (TGHA) levels in Graves' disease and Hashimoto's thyroiditis. Thirty Graves' hyperthyroid patients were treated for 14 +/- 8 months (mean +/- SD) with MMI, 60-80 mg daily or PTU, 900-1200 mg daily plus T3, 50-75 micrograms daily. Fifteen Hashimoto's thyroiditis patients (4 of whom hypothyroid) received 100-200 micrograms of T4 daily for 4-8 weeks prior to MMI, 60-90 mg daily or PTU, 900 mg daily for 12-16 weeks. In Graves' disease a decrease (p less than 0.001) in TSAb activity (20/25 patients) was observed: before therapy, 0.424 +/- 0.506 pmoles/mg wet wt and at the end of treatment, 0.189 +/- 0.23 pmoles/mg wet wt. The MCHA titers also fell (18/26 patients) from 1:10,403 +/- 20,197 to 1:3,476 +/- 5,252 (p less than 0.01) and was associated with a decrease in free T4 values (1.23 +/- 0.69 vs. 0.51 +/- 0.36 ng/dl; p less than 0.01). A fall of MCHA titers in T4-treated Hashimoto's thyroiditis patients (1:10,416 +/- 25,576) was found when compared with the value before T4 (1:25,920 +/- 39,973; p less than 0.001). However, the titers of MCHA (1:13,280 +/- 25,992) did not change on MMI or PTU plus T4 treatment. The TGHA titers fell in a single patient. No alterations were observed in serum immunoglobulins. Serum concentrations of the complement factor C'3 remained higher (p less than 0.01) than normal values in both Graves' disease and Hashimoto's thyroiditis.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2428860     DOI: 10.1007/BF03348107

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  31 in total

Review 1.  The pathogenesis of Graves' disease: an overview.

Authors:  R Volpé
Journal:  Clin Endocrinol Metab       Date:  1978-03

2.  Effects of antithyroid therapy on the long-acting thyroid stimulator and the antithyroglobulin antibodies.

Authors:  A Pinchera; P Liberti; E Martino; G F Fenzi; L Grasso; L Rovis; L Baschieri; G Doria
Journal:  J Clin Endocrinol Metab       Date:  1969-02       Impact factor: 5.958

Review 3.  Antithyroid drugs.

Authors:  D S Cooper
Journal:  N Engl J Med       Date:  1984-11-22       Impact factor: 91.245

4.  Specificity of the immunosuppressive action of carbimazole in Graves's disease.

Authors:  A M McGregor; B Rees Smith; R Hall; P N Collins; G Franco Bottazzo; M M Petersen
Journal:  Br Med J (Clin Res Ed)       Date:  1982-06-12

5.  Intrathyroidal concentrations of methimazole in patients with Graves' disease.

Authors:  R Jansson; P A Dahlberg; H Johansson; B Lindström
Journal:  J Clin Endocrinol Metab       Date:  1983-07       Impact factor: 5.958

6.  Thyroid hormones fail to influence experimental autoimmune thyroiditis.

Authors:  A P Weetman; A M McGregor; D P Rennie; R Hall
Journal:  Clin Exp Immunol       Date:  1982-10       Impact factor: 4.330

7.  Correlation between thyroid stimulators and 3,5,3'-triiodothyronine suppressibility in patients during treatment for hyperthyroidism with thionamide drugs: comparison of assays by thyroid-stimulating and thyrotropin-displacing activities.

Authors:  N Kuzuya; S C Chiu; H Ikeda; H Uchimura; K Ito; S Nagataki
Journal:  J Clin Endocrinol Metab       Date:  1979-04       Impact factor: 5.958

8.  Comparison of effects of high and low dosage regimens of antithyroid drugs in the management of Graves' hyperthyroidism.

Authors:  J H Romaldini; N Bromberg; R S Werner; L M Tanaka; H F Rodrigues; M C Werner; C S Farah; L C Reis
Journal:  J Clin Endocrinol Metab       Date:  1983-09       Impact factor: 5.958

9.  Changes of circulating thyroid autoantibody levels during and after the therapy with methimazole in patients with Graves' disease.

Authors:  C Marcocci; L Chiovato; S Mariotti; A Pinchera
Journal:  J Endocrinol Invest       Date:  1982 Jan-Feb       Impact factor: 4.256

10.  Influence of treatment with radioiodine and propylthiouracil on thyroid stimulating immunoglobulins in Graves' disease.

Authors:  K Bech; S Nistrup Madsen
Journal:  Clin Endocrinol (Oxf)       Date:  1980-11       Impact factor: 3.478

View more
  2 in total

1.  Immunological aspects of Graves' disease patients in different clinical stages.

Authors:  A Gauna; G Segura; G Sartorio; R Soto; A Segal-Eiras
Journal:  J Endocrinol Invest       Date:  1989-11       Impact factor: 4.256

2.  The evolution of Graves' ophthalmopathy during treatment with antithyroid drug alone and combined with triiodothyronine.

Authors:  N Bromberg; J H Romaldini; R S Werner; J A Sgarbi; M C Werner
Journal:  J Endocrinol Invest       Date:  1992-03       Impact factor: 4.256

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.